Eloxx Pharmaceuticals Announces Key Corporate Accomplishments
(MENAFN- GlobeNewsWire - Nasdaq) Data from Eloxx's proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm …